Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
RPTX Analyst Ratings
Moderate Buy
1 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RPTX Stock 12 Month Forecast
Average Price Target
$1.50
▼(-3.85% Downside)
| Highest Price Target$1.50 | Average Price Target$1.50 | Lowest Price Target$1.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
―
Hold
―
Reiterated
08/10/25
Repare Therapeutics: Strategic Partnerships and Cautious Optimism Amid Uncertain Trial Outcomes Justify Hold Ratings: Repare released financial results for 2Q '25 last Friday morning. The company connues to seek strategic alternaves and partnerships across its porolio, and highlighted the past quarter's efforts that included outlicensing lunreserb to Debiopharm for $10M upfront (NOTE), and a plaorm outlicensing agreement with DCx that yielded $1M upfront, $3M in near-term payments, and a 9.9% equity stake in DCx (NOTE). The company also noted an amendment to exisng collab with BMS to include an addional target. 1 LIONS trial, RPTX reiterates 4Q'25 ming for the towline dataset, where RPTX has completed enrollment of N=29 TRIM37-high solid tumors.
TD Cowen
―
Buy
―
Reiterated
08/08/25
TR | OpenAI - 4o
$1.5
Hold
-3.85%
Downside
Reiterated
08/05/25
H.C. Wainwright
$5
Buy
220.51%
Upside
Reiterated
03/07/25
Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare TherapeuticsValuation and Risks. We value Repare using a discounted cash flow (DCF)-based approach focused on the RP-3467. We ascribe a 20% probability of approval to 11% discount rate and a 1.5% terminal growth rate. Our assessment yields a total firm value of $229M, which yields a price objective of $5 per share.
Bloom Burton
―
Hold
―
Assigned
01/10/25
Piper Sandler
$6
Buy
284.62%
Upside
Assigned
01/10/25
Stifel Nicolaus
$4→$3
Buy
92.31%
Upside
Reiterated
01/10/25
Morgan Stanley
$8
Hold
412.82%
Upside
Reiterated
12/13/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
―
Hold
―
Reiterated
08/10/25
Repare Therapeutics: Strategic Partnerships and Cautious Optimism Amid Uncertain Trial Outcomes Justify Hold Ratings: Repare released financial results for 2Q '25 last Friday morning. The company connues to seek strategic alternaves and partnerships across its porolio, and highlighted the past quarter's efforts that included outlicensing lunreserb to Debiopharm for $10M upfront (NOTE), and a plaorm outlicensing agreement with DCx that yielded $1M upfront, $3M in near-term payments, and a 9.9% equity stake in DCx (NOTE). The company also noted an amendment to exisng collab with BMS to include an addional target. 1 LIONS trial, RPTX reiterates 4Q'25 ming for the towline dataset, where RPTX has completed enrollment of N=29 TRIM37-high solid tumors.
TD Cowen
―
Buy
―
Reiterated
08/08/25
TR | OpenAI - 4o
$1.5
Hold
-3.85%
Downside
Reiterated
08/05/25
H.C. Wainwright
$5
Buy
220.51%
Upside
Reiterated
03/07/25
Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare TherapeuticsValuation and Risks. We value Repare using a discounted cash flow (DCF)-based approach focused on the RP-3467. We ascribe a 20% probability of approval to 11% discount rate and a 1.5% terminal growth rate. Our assessment yields a total firm value of $229M, which yields a price objective of $5 per share.
Bloom Burton
―
Hold
―
Assigned
01/10/25
Piper Sandler
$6
Buy
284.62%
Upside
Assigned
01/10/25
Stifel Nicolaus
$4→$3
Buy
92.31%
Upside
Reiterated
01/10/25
Morgan Stanley
$8
Hold
412.82%
Upside
Reiterated
12/13/24
Best Analysts Covering Repare Therapeutics
1 Month
xxx
Success Rate
9/18 ratings generated profit
Average Return
-8.53%
assigned a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -8.53% per trade.
3 Months
xxx
Success Rate
7/18 ratings generated profit
Average Return
-13.79%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of -13.79% per trade.
1 Year
Success Rate
2/18 ratings generated profit
Average Return
-41.93%
assigned a buy rating 7 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -41.93% per trade.
2 Years
xxx
Success Rate
1/18 ratings generated profit
Average Return
-60.61%
assigned a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 5.56% of your transactions generating a profit, with an average return of -60.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RPTX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
1
1
0
0
0
Buy
1
2
1
2
2
Hold
5
11
9
15
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
14
10
17
11
Each month's total comprises the sum of three months' worth of ratings.
RPTX Financial Forecast
RPTX Stock Forecast FAQ
What is RPTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Repare Therapeutics Inc’s 12-month average price target is 1.50.
What is RPTX’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for RPTX, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RPTX a Buy, Sell or Hold?
Repare Therapeutics Inc has a consensus rating of Moderate Buy which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.
What is Repare Therapeutics Inc’s price target?
The average price target for Repare Therapeutics Inc is 1.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $1.50 ,the lowest forecast is $1.50. The average price target represents -3.85% Decrease from the current price of $1.56.
The highest analyst price target is $1.50 ,the lowest forecast is $1.50. The average price target represents -3.85% Decrease from the current price of $1.56.
What do analysts say about Repare Therapeutics Inc?
Repare Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of RPTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.